Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 12/20 | 0.47 |
| ▸ | METAP1 | P53582 | 7/20 | 0.47 |
| ▸ | REN | P00797 | 4/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27822265 | 1.00 | METAP2 (0.47) | METAP2METAP1RENCPB2KMT2A | |
| SCHEMBL2012212 | 0.90 | METAP2 (0.52) | METAP2METAP1RENCPB2KMT2A | |
| SCHEMBL742447 | 0.90 | METAP2 (0.52) | METAP2METAP1RENCPB2KMT2A | |
| SCHEMBL842176 | 0.90 | METAP2 (0.52) | METAP2METAP1RENCPB2KMT2A | |
| Hydrochloric Acid SCHEMBL744909 | 0.89 | METAP2 (0.51) | METAP2METAP1RENCPB2KMT2A | |
| Hydrochloric Acid SCHEMBL14973792 | 0.84 | METAP2 (0.56) | METAP2METAP1RENCPB2KMT2A | |
| SCHEMBL7351340 | 0.84 | METAP2 (0.56) | METAP2METAP1RENCPB2KMT2A | |
| SCHEMBL10260851 | 0.84 | METAP2 (0.48) | METAP2METAP1RENKMT2A | |
| SCHEMBL8135701 | 0.84 | METAP2 (0.48) | METAP2METAP1RENKMT2A | |
| Hydrochloric Acid SCHEMBL7361763 | 0.83 | METAP2 (0.54) | METAP2METAP1RENCPB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2237793-A1 | INHIBITORS OF CATHEPSIN B | Virobay, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009100225-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203629-A1 | INHIBITORS OF CATHEPSIN B | CTSB, CSTB, CTSF | METAP2 933/4885METAP1 456/4885REN 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.